15 Mar, 2021

SHANGHAI, China, March 15, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today that Genor Biopharma was officially included into the Heng Seng Composite Index (HSCI). This was announced by Hang Seng Index Limited according to the results of its review of the Heng Seng Family of Indexes for the quarter ended 31 December 2020, and has been effective since March 15, 2021.

 

The Hang Seng Index, the most influential index in the Hong Kong stock market, is calculated and reviewed on a quarterly basis by Hang Seng Indexes Company Limited (HSIL), a subsidiary of Hang Seng Bank Limited, which publishes the constituent stock adjustments. HSCI covers the top 95% of the total market capitalization listed on the Main Board of the Stock Exchange of Hong Kong Limited (SEHK), providing a comprehensive benchmark for the Hong Kong market. The index is calculated with weighted market capitalization method and can be used as a benchmark for the launch of index funds, mutual funds and reference standard of measurement.

 

The company's inclusion in HSCI indicates that it has met the criteria for inclusion in the Hong Kong Stock Connect. Stock Connect allows international and Chinese mainland investors to trade securities in each other’s markets through the trading and clearing platforms of their home exchanges. The expansion of the eligible stocks of Hong Kong Stock Connect, will further optimize the interconnected, intercommunicated, and mutual development of the capital markets between Chinese mainland and Hong Kong.

 

Genor Biopharma was officially listed on the Hong Kong Stock Exchange with the stock code of 6998.HK. on October 7, 2020. Genor Biopharma is a fully integrated and end-to-end innovation-driven biopharma company based in China with global reach. The company has a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer). Genor Biopharma’s inclusion in the Hong Kong Stock Connect indicates the capital market's recognition of the company's investment value and high recognition of its future development.

 

 

About Genor Biopharma

 

Founded in 2007, Genor Biopharma Co. Ltd (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer).

 

Genor Biopharma is creating a fully integrated and end-to-end biopharma innovation company based in China, with global reach. In San Francisco, the cutting-edge bispecific and multi-specific discovery platform (Antibody Therapeutics Inc.) engineers novel and highly differentiated therapeutic antibody candidates with display technology, computer-aided design, and site mutagenesis. The industry leading R&D center located in Shanghai focuses on CMC (Chemistry, Manufacturing, and Controls) development. This center is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance. In 2016, the GMP commercial manufacturing facility was built and commissioned in Yuxi, Yunan and is currently operating with a highly GMP compliant production team.  This commercial facility employs advanced continuous-flow cell culture technologies for high yield manufacturing (~20 g/L) as well as internally-developed cell culture media for cost-effective production. The site produces Phase III and pivotal trial clinical supplies, executes the commercial process validation, and performs the commercial manufacturing after product launch.

 

Genor Biopharma currently has 10+ drug candidates under development in clinical or New Drug Application (NDA) stages. Among them, the NDA for Geptanolimab (GB226) has been granted for priority review by the Center for Drug Evaluation (CDE) and has successfully passed the NDA pre-approval inspection by the National Medical Products Administration (NMPA), with a product launch targeted for 2021. It is the first PD-1 inhibitor worldwide for peripheral T-cell lymphoma (PTCL) and is expected to bring safe and high-quality therapeutic benefits to patients. The NDA filing for Infliximab (GB242) has also been accepted by CDE and is currently under review by the agency.